AssessmentsAnticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Barbiturates
Contributors:Evan Debevec-McKenney, Maria Emfietzoglou, MD, Brittany Norton, MFA, Robyn Hughes, MScBMC, Alaina Mueller
Barbiturates are a class of medications that are used as anticonvulsants to manage seizure disorders; to induce anesthesia in surgical procedures; as anxiolytics to relieve anxiety; and to manage insomnia.
Barbiturates enhance the effect of gamma-aminobutyric acid, or GABA, which is the major inhibitory neurotransmitter in the brain, by binding to its receptor.
It’s pretty well-established that your brain’s really important.
It controls your feelings, your movements, your sleep, your memory… It controls everything, whether you’re aware of it or not.
The cells that make up our brain are called neurons.
Neurons communicate with each other through neurotransmitters.
When one neuron is stimulated, it’ll release excitatory neurotransmitters like glutamate, which bind to receptors on the next neuron.
This causes the next neuron to depolarize and release its own excitatory neurotransmitters, propagating the signal throughout the brain.
Now, we also have inhibitory neurons that will shut down this chain of events.
These neurons release the main inhibitory neurotransmitter in the nervous system, gamma-aminobutyric acid, or GABA, which binds to GABA receptors on other neurons.
These receptors are large multi-unit complexes that form ligand-gated ion channels, which open up to let Cl- ions into the cell.
The influx of negatively charged ions causes hyperpolarization, where the cell’s membrane potential becomes more negative, which means it’s much more difficult for it to depolarize and fire off an action potential, and that means it’s less responsive to stimuli.
Now, there are cases where neurons in the brain start sending out more excitatory signals than normal.
This can occur due to either too much excitation by the excitatory neurotransmitters, or too little inhibition by the inhibitory neurotransmitters like GABA.
Okay, so one way we can decrease the excitatory signals is by enhancing the effect of inhibitory neurons through medication like barbiturates.
Another medication from this group is thiopental, but it’s not available in the U.S. and Canada anymore.
These medications target the GABAA receptors but they bind at a different site than GABA or benzodiazepines.
At lower doses, barbiturates enhance the effect of GABA by increasing the duration of Cl- channels opening, thereby increasing the influx of Cl- ions.
As a result, high intracellular concentrations of Cl- ions cause membrane hyperpolarization, which means it’s much more difficult for the neuron to depolarize and fire off an action potential.
So remember, barbiDurates increase duration!
At higher doses, these medications can mimic GABA effect by triggering the opening of these channels even without GABA.
In addition, barbiturates block excitatory glutamate receptors called AMPA receptors and decrease neuronal excitability; but they also inhibit voltage-gated calcium channels and decrease the release of glutamate.
Now, let’s draw a chart of the dose-dependent effects of barbiturates.
On the left side of the chart, let’s place central nervous effects; and on the bottom let’s place dose.
Now at a higher dose, barbiturates also inhibit the electron transport chain, which is a process that occurs within the inner mitochondrial membrane and results in the synthesis of adenosine triphosphate, or ATP.
ATP is the main form of energy that keeps all of our body cells going.
So when the electron transport chain gets interrupted, the ATP synthesis doesn’t happen and that can eventually lead to the death of the cell.
Barbiturates also induce a class of enzymes called cytochrome P450.
Increased cytochrome P450 activity can cause these medications to break down more rapidly, so larger doses may be needed to achieve a therapeutic effect.
Alright, now barbiturates are indicated when the neurons get “super excited” and we want to calm them down, like during an epileptic seizure where clusters of neurons in the brain become temporarily impaired and start firing off a ton of excitatory signals.
Moreover, PHENobarbital is the first-line treatment for neonatal convulsions.
Also, this feature makes them useful for treating acute anxiety states like a panic attack.
In addition, barbiturates can be used for preoperative sedation and to induce anesthesia; but they can also be given as a hypnotic to induce sleep since we basically want to depress the function of the person’s nervous system.
Finally, in life-threatening conditions, such as increased intracranial pressure, these medications can be used to decrease cerebral blood flow and induce coma, which is also known as the barbiturate-induced coma.
Moving on to side effects, barbiturates can have severe adverse effects even when used at therapeutic levels.
They can cause drowsiness, as well as a decrease in concentration, problem solving ability, and reaction time, so it’s important not to drive while taking these medications.
Despite being a central nervous system depressant, barbiturates can cause paradoxical stimulation in certain parts of the brain, leading to symptoms like fast speech, excitement, and restlessness.
Now, it’s important to note that barbiturate overdose can’t be treated with flumazenil, which is an antidote used in benzodiazepine overdose!
- "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
- "Rang and Dale's Pharmacology" Elsevier (2019)
- "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
- "Does bright light have an anxiolytic effect? - an open trial" BMC Psychiatry (2007)
- "The use of phenobarbital and other anti-seizure drugs in newborns" Seminars in Fetal and Neonatal Medicine (2017)
- "Pediatric Epilepsy" Demos Medical Pub (2001)
- "Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital, and methylphenylethylhydantoin in motor seizures" Clinical Pharmacology & Therapeutics (1962)